ClinicalTrials.gg
Not yet recruitingNCT04273347BENTHOSUpdated Aug 31, 2023

Incidence of Neurogenic Paraosteoarthropathies in a Population of Brain Traumatized and Spinal Cord Injured Patients and Specific Markers of Early NPOA Development"

An observational study in Spinal Cord Injuries and Injury, Brain, Traumatic, sponsored by Assistance Publique - Hôpitaux de Paris. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-08-31.

Sponsored by Assistance Publique - Hôpitaux de Paris · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Nov 2024, 2 years ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
118
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Spinal Cord Injuries by Assistance Publique - Hôpitaux de Paris — 1 open to participants now, 1 under way, none of them phase 3. Spinal Cord Injuries · Assistance Publique - Hôpitaux de Paris.

Started
2023
the only one that year
Observational
2 of 11
1 open now
Registered
6th of 11
by date

Among the 11 studies in Spinal Cord Injuries by Assistance Publique - Hôpitaux de Paris, this one is the only one that started in 2023, is one of 2 observational ones, and was the 6th registered.

Spinal Cord Injuries

2,032 studies on the registry are indexed under Spinal Cord Injuries; 542 are open to participants now.

Browse Spinal Cord Injuries studies →

Open to participants now

1 of the 11 studies in Spinal Cord Injuries by Assistance Publique - Hôpitaux de Paris is open now.

Where they have run

Who these studies take

Of the 374 Spinal Cord Injuries studies recruiting now, 167 (45%) set no upper age limit and 156 (42%) stop at 75 or younger; 40 take children under 18; 52 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Spinal Cord Injuries by Assistance Publique - Hôpitaux de Paris, or all of them as a file.
02

Study summary

Neurogenic paraosteoarthropathies are peri-articular bone formations that may occur as a result of central neurological injury. Their occurrence limits reeducation and recovery capacities. Neurogenic paraosteoarthropathies sometimes cause complications (pain, joint stiffness, vascular and nerve compression, pressure sores) in patients already suffering from severe neurological sequelae affecting functional prognosis. A lot of clinical research work has been carried out within Dr Salga team. Subsequently, a collaboration was born with fundamental research teams (Pr Levesque, Pr Le Bousse Kerdilès, Pr Banzet, Pr Genêt) allowing translational work between humans and animals. The clinical application of recent research findings now makes it possible to launch the very first prospective study on neurogenic paraosteoarthropathies.

Read the detailed description

Based on the results of collaborative and translational (human-animal) work, investigators wish to conduct the first prospective study that would allow:

(i) To assess the incidence of Neurogenic paraosteoarthropathies (clinical suspicion and radiological confirmation). The prospective nature of this clinical data collection will make it possible to avoid the biases attributed to the retrospective studies conducted to date.

ii) Early detection of patients at risk of developing Neurogenic paraosteoarthropathies, using specific biomarkers and clinical parameters. Early diagnosis could prevent complications and functional impact of Neurogenic paraosteoarthropathies.

Investigators have chosen to restrict population to patients most at risk of developing Neurogenic paraosteoarthropathies as a result of the central neurological event in order to have 2 populations appear at the end of the study: a population with Neurogenic paraosteoarthropathies and a population without Neurogenic paraosteoarthropathies that can be compared.

03

Conditions studied

  • Spinal Cord Injuries
  • Injury, Brain, Traumatic
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

patient with brainTrauma or spinal cord injury upon arrival in intensive care

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or Female > 18 years old,
  • brain trauma with initial Glasgow score \< 8,
  • or brain trauma with an initial Glasgow score between 8 and 14 associated with an Injury Severity Score (ISS) > 15 and surgery within 24 hours of admission or traumatic spinal cord injury with complete neurological impairment (initial para/tetraplegia),
  • Complete traumatic spinal cord injury. Accident less than 48 hours old
  • signed by the patient or a family member

Exclusion criteria

Exclusion Criteria:

  • Age \< 18 years,
  • Hemorrhagic shock or blood transfusion greater than or equal to 4 red blood cells within 6 hours of the trauma (also include pre-hospital or first hospital red blood cells)
  • Follow-up impossible over one year,
  • Patient not living in the Paris region,
  • Pregnant or breastfeeding woman,
  • Patient under guardianship or curatorship,
  • No affiliation to a social security scheme or universal mutual fund.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
118 participants (estimated)
Patient registry
No

Groups and cohorts

  • patient with brain trauma

    all patient with brain trauma in intensive care unit

    Other: standard of care for patient with brain trauma and spinal cord injury

  • patient with spinal cord injury

    all patient with spinal cord injury in intensive care unit

    Other: standard of care for patient with brain trauma and spinal cord injury

Interventions

  • Otherstandard of care for patient with brain trauma and spinal cord injury

    neurological examination, examination of articulation, infectious status, respiratory status, inflammatory status,kinesitherapy

06

What researchers measure

Primary outcomes

  1. Incidence of Neurogenic Paraosteoarthropathies

    Determine the incidence of Neurogenic Paraosteoarthropathies within 9 months of a brain trauma and/or spinal cord injury

    Time frame: 9 months

Secondary outcomes

  1. the incidence of Neurogenic Paraosteoarthropathies development within 9 months of a brain trauma

    determine the incidence of Neurogenic Paraosteoarthropathies development within 9 months of a brain trauma

    Time frame: 9 months

  2. the incidence of Neurogenic Paraosteoarthropathies development within 9 months of a spinal cord injury,

    determine the incidence of Neurogenic Paraosteoarthropathies development within 9 months of a spinal cord injury,

    Time frame: 9 months

  3. correlation between biological parameters from blood/plasma, urine and cerebrospinal fluid within 15 days of a central neurological injury and the occurrence of Neurogenic Paraosteoarthropathies within 9 months of the trauma

    Determine if there is an correlation between biological parameters from blood/plasma, urine and cerebrospinal fluid within 15 days of a central neurological injury and the occurrence of POAN within 9 months of the trauma

    Time frame: 15 days

  4. a correlation between clinical parameters identified within 9 months of the neurological event and the occurrence of Neurogenic Paraosteoarthropathies within one year of the trauma,

    Determine if there is a correlation between clinical parameters identified within 9 months of the neurological event and the occurrence of Neurogenic Paraosteoarthropathies within one year of the trauma,

    Time frame: 12 months

  5. a clinical-biological risk score for Neurogenic Paraosteoarthropathies within 9 months of the trauma

    Create a clinical-biological risk score for Neurogenic Paraosteoarthropathies within 9 months of the trauma

    Time frame: 9 months

  6. the prognostic performance

    Calculate the prognostic performance (of POAN occurrence in the year after the trauma) for the biological parameters statistically associated with Neurogenic Paraosteoarthropathies occurrence and for the risk score

    Time frame: 12 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Torossian F, Guerton B, Anginot A, Alexander KA, Desterke C, Soave S, Tseng HW, Arouche N, Boutin L, Kulina I, Salga M, Jose B, Pettit AR, Clay D, Rochet N, Vlachos E, Genet G, Debaud C, Denormandie P, Genet F, Sims NA, Banzet S, Levesque JP, Lataillade JJ, Le Bousse-Kerdiles MC. Macrophage-derived oncostatin M contributes to human and mouse neurogenic heterotopic ossifications. JCI Insight. 2017 Nov 2;2(21):e96034. doi: 10.1172/jci.insight.96034. PubMed 29093266 ↗
  • Reznik JE, Biros E, Marshall R, Jelbart M, Milanese S, Gordon S, Galea MP. Prevalence and risk-factors of neurogenic heterotopic ossification in traumatic spinal cord and traumatic brain injured patients admitted to specialised units in Australia. J Musculoskelet Neuronal Interact. 2014 Mar;14(1):19-28. PubMed 24583537 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2023; primary completion for Nov 2024, 14 months later.

Of 124 non-industry observational studies under Spinal Cord Injuries, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 74. This study's planned 14 months is below that.

Counting every sponsor, half of 135 studies reached it within 39 months; a quarter within 16 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 22, 2019
First posted
Feb 18, 2020
StartEst.
Sep 15, 2023
Primary completionEst.
Nov 15, 2024
CompletionEst.
Dec 15, 2024
Last update
Aug 31, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 31, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04273347
Responsible party
Sponsor
First posted
Feb 18, 2020
Start date
Sep 15, 2023 (estimated)
Primary completion
Nov 15, 2024 (estimated)
Completion
Dec 15, 2024 (estimated)
Last update
Aug 31, 2023

Study contacts

Marjorie salga, MD
Contact
marjorie.salga@aphp.fr
+33 1 47 10 70 82
François Genet, Professor
Contact
francois.genet@aphp.fr
+331 47 10 70 70
Majorie Salga, MD
principal investigator · Hôpital Raymond Poincaré

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion